BJH - volume 11, issue Abstract Book BHS, february 2020
E. Linskens , S. Van Landeghem , K. Vandepoele PhD, dr. K. Maes , I. Moors MD, dr. J. Van Dorpe , C. Bonroy , K. Devreese , J. Philippé MD, PhD, B. Denys MD
BJH - volume 11, issue Abstract Book BHS, february 2020
E. De Backer , P. Vlummens MD, R. Callens MD, I. Moors MD
BJH - volume 11, issue Abstract Book BHS, february 2020
E. Janssens , dr. J. Van Dorpe , V. Van Hende MD, I. Moors MD, P. Vlummens MD, C. De Vriendt
BJH - volume 11, issue Abstract Book BHS, february 2020
S. Bonte PhD, S. Van Gassen , A. Couckuyt , V. Janda , I. Moors MD, dr. A. Delie MD, S. Kennes MD, J. Philippé MD, PhD, Y. Saeys , T. Kerre MD, PhD
BJH - volume 9, issue 7, december 2018
dr. A. Delie MD, T. Kerre MD, PhD, I. Moors MD
Since several years, it has become clear that intermediate-risk acute myeloid leukaemia patients in an acceptable clinical condition can benefit from allogeneic stem cell transplantation thanks to the improvement in relapse free survival. This study retrospectively analysed the outcome of all intermediate-risk acute myeloid leukaemia patients treated with intensive chemotherapy at the Ghent University Hospital between 01-01-2013 and 30-04-2017 in an effort to determine the impact of a new in-hospital treatment guideline adopted in April 2015. This guideline recommends all intermediate-risk acute myeloid leukaemia patients who are fit for intensive therapy to proceed to allogeneic stem cell transplantation in first complete remission. Unfortunately, we could not demonstrate an improvement in the relapse free survival after implementation of the treatment guideline. Nevertheless, exploratory analysis of the entire group suggests a survival benefit from allogeneic stem cell transplantation, with significantly improved relapse free survival and a trend towards a better overall survival.
(BELG J HEMATOL 2018;9(7):285–9)
Read moreBJH - volume 9, issue 6, november 2018
K. Imaeva , I. Moors MD, dr. J. Van Dorpe , S. Verbeke , B. Denys MD
Blastic plasmacytoid dendritic cell neoplasm is a highly aggressive myeloid neoplasm with a high rate of central nervous system recurrence. We present a case to illustrate central nervous system involvement and possible treatment options.
(BELG J HEMATOL 2018;9(6):237–41)
Read moreBJH - 2018, issue Abstract Book BHS, february 2018
K. Imaeva , P. Vlummens MD, S. Verbeke , J. Philippé MD, PhD, I. Moors MD
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.